Loading...
•
Mar 31, 2025
Castle Biosciences Q1 2025 Earnings Report
Reported financial results for the first quarter ended March 31, 2025
Key Takeaways
Castle Biosciences reported a strong start to 2025 with significant increases in revenue and test report volume in the first quarter, driven by core revenue drivers like DecisionDx-Melanoma and DecisionDx-SCC. The company also raised its full-year 2025 revenue guidance.
Q1 2025 revenue increased 21% compared to Q1 2024, reaching $88 million.
Total test reports for core revenue drivers (DecisionDx-Melanoma, DecisionDx-SCC, TissueCypher) increased 33% over Q1 2024.
DecisionDx-Melanoma surpassed 200,000 test orders since its launch.
The company raised its full-year 2025 revenue guidance to $287-297 million.
Forward Guidance
Castle Biosciences raised its full-year 2025 revenue guidance.
Positive Outlook
- Increased full-year 2025 revenue guidance.
- Strong performance in Q1 2025 with significant revenue and test volume growth.
- Continued growth expected for core revenue drivers.
- DecisionDx-Melanoma reaching a significant milestone of over 200,000 orders.
- Belief in the high clinical value of their tests and consistent execution.
Challenges Ahead
- No specific negative forward guidance mentioned in the report.
- Reliance on continued market acceptance and reimbursement for tests.
- Potential impacts of competition not explicitly addressed in guidance.
- Execution risk in expanding into new therapeutic areas.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...